Drug Trial Radar · NCT07547813
A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
May 13, 2026
Primary completion
Feb 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Almirall, S.A.Industry
- Sponsor type
- Industry
- First posted
- Apr 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the effect of LAD328 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS), and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.
Conditions
- Hidradenitis Suppurativa
Interventions
LAD328Drug
LAD328 administered intravenously.
PlaceboOther
Placebo administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving 55 Percent (%) Reduction from Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4-55)Time frame: At Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Alm Site 1
Warsaw, Masovian Voivodeship, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.